financetom
Business
financetom
/
Business
/
Market Chatter: Blackstone, Warburg Explore Options for IntraFi Including Potential Sale
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Blackstone, Warburg Explore Options for IntraFi Including Potential Sale
Nov 15, 2024 12:31 PM

03:02 PM EST, 11/15/2024 (MT Newswires) -- Blackstone (BX) and private equity firm Warburg Pincus are evaluating strategic options including a sale of financial technology services provider IntraFi, Bloomberg reported, citing people familiar with the matter.

The two alternative-asset managers have started discussions with investment banks to gauge interest in IntraFi, which could be valued at $12 billion or more in a transaction slated for early 2025.

Large financial technology firms, including exchanges, could be potential buyers, according to the news outlet.

Alternatively, IntraFi might pursue an initial public offering.

Blackstone and Warburg have not yet made a final decision and could opt to keep the business, the report added.

Blackstone declined MT Newswires' request for comment. Warburg and IntraFi did not immediately respond.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 180.60, Change: -0.61, Percent Change: -0.34

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Spectral Medical Says 105 Patients Now Enrolled in Tigris Trial
Spectral Medical Says 105 Patients Now Enrolled in Tigris Trial
May 6, 2024
08:16 AM EDT, 05/06/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) , which is advancing therapeutic options for sepsis and septic shock, on Monday provided an update on its Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (PMX) in a trial of adults treated for endotoxemia and septic shock. The company reports that...
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition
May 6, 2024
May 6 (Reuters) - Gossamer Bio ( GOSS ) said on Monday it will collaborate with Italian drugmaker Chiesi Group to develop and commercialize its therapy seralutinib in multiple indications related to high blood pressure due to constriction of lung arteries. The therapy is currently in late-stage development for the treatment of pulmonary arterial hypertension (PAH), which affects about 40,000...
LSL Pharma to Acquire Quebec Competitor for $2.5 Million to Expand Natural-Product Offerings
LSL Pharma to Acquire Quebec Competitor for $2.5 Million to Expand Natural-Product Offerings
May 6, 2024
08:18 AM EDT, 05/06/2024 (MT Newswires) -- LSL Pharma Group ( LPGIF ) on Monday said it will acquire a rival pharmaceutical manufacturer for $2.5 million in cash to expand its contract-manufacturing of natural health products. LSL identified the company only as a Quebec-based competing contract drug manufacturer (CDMO) specialized in the formulation, production, and marketing of natural products. LSL...
Block Plans $1.5 Billion Senior Notes Offering
Block Plans $1.5 Billion Senior Notes Offering
May 6, 2024
08:18 AM EDT, 05/06/2024 (MT Newswires) -- Block (SQ) said Monday it plans a private placement of $1.5 billion in senior notes. The company and the purchasers have yet to set the interest rate, redemption provisions, maturity date, and other terms of the notes. Block intends to use the net proceeds from this offering for general corporate purposes, which may...
Copyright 2023-2026 - www.financetom.com All Rights Reserved